UK cost watchdog recommends Novartis' blindness therapy Luxturna [Reuters (UK)]
SPARK THERAPEUTICS INC (ONCE)
Last spark therapeutics inc earnings: 11/7 04:35 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.sparktx.com/investor-overview
Company Research
Source: Reuters
UK cost watchdog recommends Novartis' blindness therapy Luxturna - Reuters 2 Min Read (Reuters) - Novartis AG’s ( NOVN.S ) gene therapy for blindness, Luxturna, is recommended for use on England’s public health service, the country’s healthcare cost-effectiveness watchdog NICE said on Tuesday. Novartis owns the rights to sell the one-time gene therapy developed by Spark Therapeutics ( ONCE.O ) outside the United States. The decision by the National Institute for Health and Care Excellence (NICE) comes as a boost to the Swiss drugmaker, which had come under regulatory scrutiny for data discrepancy issues related to its $2 million gene therapy, Zolgensma. Novartis has been expanding into gene and cell therapies for rare diseases and licensed Luxturna last year, for $105 million upfront, up to another $65 million in milestone payments, and royalties on sales. The gene therapy, injected directly into the retina, won EU approval last November, to treat patients suffering from inherited
Show less
Read more
Impact Snapshot
Event Time:
ONCE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ONCE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ONCE alerts
High impacting SPARK THERAPEUTICS INC news events
Weekly update
A roundup of the hottest topics